Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.

PURPOSE: We aimed to identify signaling pathways involved in the response and resistance to aromatase inhibitor therapy in patients with breast cancer. PATIENTS AND METHODS: One hundred fourteen women with T2-4 N0-1, estrogen receptor (ER) alpha-positive tumors were randomly assigned to neoadjuvant...

Bibliografiset tiedot
Päätekijät:	Generali, D, Buffa, F, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Papotti, M, Dogliotti, L, Bottini, A, Harris, A, Fox, S
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	2009

Samankaltaisia teoksia

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
Tekijä: Fox, S, et al.
Julkaistu: (2011)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
Tekijä: Fox, S, et al.
Julkaistu: (2011)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
Tekijä: Generali, D, et al.
Julkaistu: (2006)

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.
Tekijä: Generali, D, et al.
Julkaistu: (2006)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
Tekijä: Mele, T, et al.
Julkaistu: (2010)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
Tekijä: Mele, T, et al.
Julkaistu: (2010)

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
Tekijä: Generali, D, et al.
Julkaistu: (2009)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
Tekijä: Generali, D, et al.
Julkaistu: (2007)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
Tekijä: Generali, D, et al.
Julkaistu: (2007)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
Tekijä: Generali, D, et al.
Julkaistu: (2006)

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Tekijä: Generali, D, et al.
Julkaistu: (2008)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
Tekijä: Generali, D, et al.
Julkaistu: (2008)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
Tekijä: Fox, S, et al.
Julkaistu: (2006)

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
Tekijä: Generali, D, et al.
Julkaistu: (2011)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
Tekijä: Foroni, C, et al.
Julkaistu: (2009)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
Tekijä: Allevi, G, et al.
Julkaistu: (2013)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
Tekijä: Allevi, G, et al.
Julkaistu: (2013)

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer
Tekijä: Andreis, D, et al.
Julkaistu: (2016)

Mammary epithelial cell phenotype disruption in vitro and in vivo through ERalpha36 overexpression.
Tekijä: Charlène Thiebaut, et al.
Julkaistu: (2017-01-01)

An alkylphenol mix promotes seminoma derived cell proliferation through an ERalpha36-mediated mechanism.
Tekijä: Hussein Ajj, et al.
Julkaistu: (2013-01-01)

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
Tekijä: A Ianza, et al.
Julkaistu: (2020-06-01)

Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.
Tekijä: Magdalena Cizkova, et al.
Julkaistu: (2010-12-01)

Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1α.
Tekijä: Coutts, A, et al.
Julkaistu: (2011)

Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1α
Tekijä: Coutts, A, et al.
Julkaistu: (2011)

Substrate‐dependent control of MAPK phosphorylation in vivo
Tekijä: Yoosik Kim, et al.
Julkaistu: (2011-02-01)

MAPK Phosphorylation Assay with Leaf Disks of Arabidopsis
Tekijä: Pascale Flury, et al.
Julkaistu: (2013-10-01)

The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
Tekijä: Milani, M, et al.
Julkaistu: (2009)

Phosphorylation of NEUROG3 links endocrine differentiation to the cell cycle in pancreatic progenitors
Tekijä: Krentz, NAJ, et al.
Julkaistu: (2017)

Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival.
Tekijä: Giatromanolaki, A, et al.
Julkaistu: (2012)

Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival
Tekijä: Giatromanolaki, A, et al.
Julkaistu: (2011)

Changes in Oxidative Phosphorylation Activity in Fibroblasts at p38 MAPK Pathway Inhibition
Tekijä: Irina A Shurygina, et al.
Julkaistu: (2019-12-01)

Systemic Sympathoexcitation Was Associated with Paraventricular Hypothalamic Phosphorylation of Synaptic CaMKIIα and MAPK/ErK
Tekijä: Olalekan M. Ogundele, et al.
Julkaistu: (2017-08-01)

Pα-syn* mitotoxicity is linked to MAPK activation and involves tau phosphorylation and aggregation at the mitochondria
Tekijä: Diego Grassi, et al.
Julkaistu: (2019-04-01)

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network
Tekijä: Ciuffreda Libero, et al.
Julkaistu: (2009-11-01)

Phosphorylation of Npas4 by MAPK Regulates Reward-Related Gene Expression and Behaviors
Tekijä: Yasuhiro Funahashi, et al.
Julkaistu: (2019-12-01)

Phosphorylation of MAPK-like proteins in three intertidal macroalgae under stress conditions
Tekijä: ML Parages, et al.
Julkaistu: (2014-11-01)

Data on the phosphorylation of p38MAPK and JNK induced by chlorpyrifos in Drosophila melanogaster
Tekijä: J.E.S. Batista, et al.
Julkaistu: (2016-12-01)

Suppression of PGE2 production via disruption of MAPK phosphorylation by unsymmetrical dicarbonyl curcumin derivatives
Tekijä: Aluwi, Mohd Fadhlizil Fasihi Mohd, et al.
Julkaistu: (2017)

Crystal structure of the phosphorylated Arabidopsis MKK5 reveals activation mechanism of MAPK kinases
Tekijä: Pei Chao-Jun, et al.
Julkaistu: (2022-07-01)

Phosphorylation of a WRKY transcription factor by MAPKs is required for pollen development and function in Arabidopsis.
Tekijä: Yuefeng Guan, et al.
Julkaistu: (2014-01-01)